Eli Lilly Completes Acquisition of Centessa Pharmaceuticals, Expanding Treatment Portfolio for Sleep Disorders

Eli Lilly and Company has successfully finalized its acquisition of Centessa Pharmaceuticals plc, a clinical-stage company focused on developing orexin receptor 2 agonists to address narcolepsy and sleep-wake disorders. Carole Ho, Lilly executive vice president and president of Lilly Neuroscience, emphasized the significant impact of the orexin system on brain health and the potential to address various sleep-related conditions.

Lilly aims to expedite the exploration of Centessa's clinical portfolio to address the unmet needs in treating disrupted sleep. Additionally, Lilly is committed to utilizing biotechnology, chemistry, and genetic medicine to advance solutions for diabetes care, obesity, Alzheimer's disease, immune system disorders, and challenging cancers. The company's dedication to enhancing global health extends to promoting diverse clinical trials and ensuring the accessibility and affordability of its medicines.

For further details about the acquisition and Centessa's clinical-stage pipeline, refer to Lilly's official website. The trademarks and trade names mentioned in this press release are the property of Lilly and their respective owners. The press release also includes cautionary statements regarding forward-looking statements, highlighting the risks and uncertainties associated with the acquisition process and drug development.